|
|
Blood, 1 November 2005, Vol. 106, No. 9, pp. 3049-3054.
Prepublished online as a Blood First Edition Paper on July 19, 2005; DOI 10.1182/blood-2005-03-0912.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study
Paolo Prandoni,
Sergio Siragusa,
Bruno Girolami,
Fabrizio Fabris, for the BELZONI Investigators Group
From the Scienze Mediche e Chirurgiche, Clinica Medica II, Università di Padova, Padova, Italy; Malattie Tromboemboliche ed Emorragiche, Ematologia con Trapianto, Azienda Ospedaliera Universitaria di Palermo, Palermo, Italy; Medicina Generale, Azienda Ospedaliera di Padova, Padova, Italy; Scienze Mediche e Chirurgiche, Medicina Interna, Università di Padova, Padova, Italy.
In contrast with extensive documentation in patients treated with unfractionated heparin (UFH), the incidence of heparin-induced thrombocytopenia (HIT) in medical patients receiving low-molecular-weight heparin (LMWH) is less well defined. In a prospective cohort study, the platelet count was monitored in 1754 consecutive patients referred to 17 medical centers and treated with LMWH for prophylaxis or treatment of thromboembolic disorders. The diagnosis of HIT was accepted in case of a platelet drop of at least 50%, the absence of obvious explanations for thrombocytopenia, and the demonstration of heparin-dependent IgG antibodies. HIT developed in 14 patients (0.80%; 95% CI, 0.43%-1.34%), in all of them within the first 2 weeks, and was more frequent in patients who had (1.7%) than in those who had not (0.3%) been exposed to UFH or LMWH (OR = 4.9; 95% CI, 1.5-15.7). The prevalence of thromboembolic complications in HIT patients (4 of 14; 28.6%) was remarkably higher than that (41 of 1740; 2.4%) observed in the remaining patients (OR = 16.6; 95% CI, 5.0-55.0). Immune thrombocytopenia and related thromboembolism may complicate the clinical course of medical patients treated with LMWH with a frequency that is not different from that observed with the use of UFH. The previous administration of heparin increases the rate of HIT.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Unfractionated LMWH and the risk of HIT: are medical patients different?
- Theodore E. Warkentin and Andreas Greinacher
Blood 2005 106: 2931-2932.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
G. F. Pineo and R. D. Hull
Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2009;
15(5):
489 - 500.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J ten Berg, P. M. van den Bemt, A. Huisman, A. F. Schobben, T. C. Egberts, and W. W van Solinge
Compliance with Platelet Count Monitoring Recommendations and Management of Possible Heparin-Induced Thrombocytopenia in Hospitalized Patients Receiving Low-Molecular-Weight Heparin
Ann. Pharmacother.,
September 1, 2009;
43(9):
1405 - 1412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Elalamy, G. Le Gal, F. Nachit-Ouinekh, A. Lafuma, C. Emery, C. Le-Fur, and F. Chapuis
Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France
Clinical and Applied Thrombosis/Hemostasis,
August 1, 2009;
15(4):
428 - 434.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Smythe, J. M. Koerber, M. Fitzgerald, and J. C. Mattson
The Financial Impact of Heparin-Induced Thrombocytopenia
Chest,
September 1, 2008;
134(3):
568 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
340S - 380S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. B. F. Oliveira, E. M. Crespo, R. C. Becker, E. F. Honeycutt, C. S. Abrams, K. J. Anstrom, P. B. Berger, L. D. Davidson-Ray, E. L. Eisenstein, N. S. Kleiman, et al.
Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
Arch Intern Med,
January 14, 2008;
168(1):
94 - 102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Demir, E. Duran, O. Yigitbasi, O. Vural, T. Kurum, M. Yuksel, B. Turgut, J. M. Walenga, and J. Fareed
Incidence of Antiheparin-Platelet Factor 4 Antibodies and Heparin-Induced Thrombocytopenia in Turkish Patients Undergoing Cardiac Surgery
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2007;
13(3):
279 - 284.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Smythe, J. M. Koerber, and J. C. Mattson
The Incidence of Recognized Heparin-Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital
Chest,
June 1, 2007;
131(6):
1644 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Siragusa, A. Malato, F. Falaschi, F. Porro, R. Anastasio, A. Giarratano, L. L. Coco, M. C. Buonanno, E. Maggi, M. A. Bressan, et al.
Deferral of assessment of pulmonary embolism
Haematologica,
March 1, 2007;
92(3):
410 - 413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Harrington and A. Jindeel
Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism
JAMA,
January 17, 2007;
297(3):
262 - 262.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Blood,
November 1, 2006;
108(9):
2937 - 2941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Arepally and T. L. Ortel
Heparin-Induced Thrombocytopenia
N. Engl. J. Med.,
August 24, 2006;
355(8):
809 - 817.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Prandoni
How I treat venous thromboembolism in patients with cancer
Blood,
December 15, 2005;
106(13):
4027 - 4033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
